Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation

Vaccine

Volumn 28, Issue 34, 2010, Pages 5543-5550

  Stegmann, Toon ^a,b   Kamphuis, Tobias ^a   Meijerhof, Tjarko ^a   Goud, Ellen ^b   de Haan, Aalzen ^a   Wilschut, Jan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Mymetics BV (formerly Virosome Biologicals)   (Netherlands)

Author keywords

Respiratory syncytial virus; Vaccine; Virosomes

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; LIPOPEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIROSOME VACCINE; IMMUNOLOGICAL ADJUVANT; VIROSOME; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN PRESENTATION; ARTICLE; COTTON RAT; CYTOKINE RELEASE; DRUG FORMULATION; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TH1 CELL; TH2 CELL; VIRUS ENVELOPE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SERODIAGNOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGEN PRESENTATION; FEMALE; INTERFERON-GAMMA; LIPOPEPTIDES; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RATS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL ENVELOPE PROTEINS; VIROSOMES;

EID: 77955053788     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.041     Document Type: Article

References (27)

1. van Drunen Littel-van den Hurk S., Mapletoft J.W., Arsic N., Kovacs-Nolan J. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 2007, 17(January-February (1)):5-34.
2. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352(April (17)):1749-1759.
3. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89(April (4)):422-434.
4. Waris M.E., Tsou C., Erdman D.D., Zaki S.R., Anderson L.J. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 1996, 70(5):2852-2860.
5. Delgado M.F., Coviello S., Monsalvo A.C., Melendi G.A., Hernandez J.Z., Batalle J.P., et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009, 15(January (1)):34-41.
6. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 1990, 8(October (5)):497-502.
7. Boukhvalova M.S., Prince G.A., Soroush L., Harrigan D.C., Vogel S.N., Blanco J.C. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine 2006, 24(June (23)):5027-5035.
8. Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache A.M., et al. The virosome concept for influenza vaccines. Vaccine 2005, 23(July (Suppl. 1)):S26-38.
9. Usonis V., Bakasenas V., Valentelis R., Katiliene G., Vidzeniene D., Herzog C. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine 2003, 21(November (31)):4588-4592.
10. Daemen T., de Mare A., Bungener L., de Jonge J., Huckriede A., Wilschut J. Virosomes for antigen and DNA delivery. Adv Drug Deliv Rev 2005, 57(January (3)):451-463.
11. Dijkstra J., Bron R., Wilschut J., de Haan A., Ryan J.L. Activation of murine lymphocytes by lipopolysaccharide incorporated in fusogenic, reconstituted influenza virus envelopes (virosomes). J Immunol 1996, 157(3):1028-1036.
12. de Vries J.J., Bungener L., Ter Veer W., van Alphen L., van der Ley P., Wilschut J., et al. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. Vaccine 2009, 27(February (6)):947-955.
13. Cusi M.G., Zurbriggen R., Correale P., Valassina M., Terrosi C., Pergola L., et al. Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity. Vaccine 2002, 20(October (29-30)):3436-3442.
14. de Jonge J., Schoen P., ter Veer W., Stegmann T., Wilschut J., Huckriede A. Use of a dialyzable short-chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes. Biochim Biophys Acta 2006, 1758(April (4)):527-536.
15. Bessler W.G., Heinevetter L., Wiesmüller K.H., Jung G., Baier W., Huber M., et al. Bacterial cell wall components as immunomodulators. I. Lipopeptides as adjuvants for parenteral and oral immunization. Int J Immunopharmacol 1997, 19(January (9-10)):547-550.
16. Gupta C.K., Leszczynski J., Gupta R.K., Siber G.R. Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Vaccine 1996, 14(15):1417-1420.
17. Böttcher C.J.F., Van Gent C.M., Fries C. A rapid and sensitive sub-micro phosphorous determination. Anal Chim Acta 1961, 24:203-204.
18. Prince G.A., Jenson A.B., Hemming V.G., Murphy B.R., Walsh E.E., Horswood R.L., et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol 1986, 57(3):721-728.
19. Ponimaskin E., Bareesel K.K., Markgraf K., Reszka R., Lehmann K., Gelderblom H.R., et al. Sendai virosomes revisited: reconstitution with exogenous lipids leads to potent vehicles for gene transfer. Virology 2000, 269(April (2)):391-403.
20. Moore M.L., Peebles R.S. Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics. Pharmacol Ther 2006, 112(November (2)):405-424.
21. Connors M., Collins P.L., Firestone C.Y., Sotnikov A.V., Waitze A., Davis A.R., et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 1992, 10(7):475-484.
22. Falsey A.R., Walsh E.E., Capellan J., Gravenstein S., Zambon M., Yau E., et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis 2008, 198(November (9)):1317-1326.
23. Sakurai H., Williamson R.A., Crowe J.E., Beeler J.A., Poignard P., Bastidas R.B., et al. Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines. J Virol 1999, 73(4):2956-2962.
24. Johnson P.R., Olmsted R.A., Prince G.A., Murphy B.R., Alling D.W., Walsh E.E., et al. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol 1987, 61(10):3163-3166.
25. Kessi J., Poiree J.C., Wehrli E., Bachofen R., Semenza G., Hauser H. Short-chain phosphatidylcholines as superior detergents in solubilizing membrane proteins and preserving biological activity. Biochemistry 1994, 33(September (35)):10825-10836.
26. 2+-ATPase from sarcoplasmic reticulum: solubilization and reconstitution by new short-chain phospholipid detergent 1,2-diheptanoyl-sn-phosphatidylcholine. Biochem J 1997, 325(July (Pt 2)):533-542.
27. Langley J.M., Sales V., McGeer A., Guasparini R., Predy G., Meekison W., et al. A dose-ranging study of a subunit respiratory syncytial virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults >/=65 years of age. Vaccine 2009, (July (31)).